摘要
背景与目的放射性125I粒子组织内植入治疗,具有对肿瘤组织高度适形,低剂量长时间照射的特点。本研究通过测定125I粒子植入治疗前后肺癌患者血清CEA、CA125、NSE、CYFRA21-1等肿瘤标志物水平,观察125I粒子植入前后肿瘤标志物的变化,观察肿瘤治疗疗效分级与肿瘤标志物水平的关系。方法用放射免疫方法测定125I粒子植入治疗肺癌患者前后血清中CEA、CA125、NSE、CYFRA21-1的浓度。结果125I粒子植入1月后,肺癌患者血清中CEA、CA125、NSE、CYFRA21-1等肿瘤标志物与植入前比较即出现明显变化(P<0.01)。125I粒子植入后1个月、3个月、6个月上述肿瘤标志物水平各组间比较无明显差异。结论125I粒子植入治疗肺癌能够有效的降低多项肿瘤标志物的水平,不同的疗效分级的肿瘤标志物水平明显不同。
Background and objective The braehytherapy with iodine seeds is characterized by radioactive 125Ⅰ very close to or in contact with the target organ. This study is to evaluate the clinical value of implanted radioactive 125Ⅰ-seed in the treatment of lung cancer patients. Methods Sixty-three cases of lung cancer were enrolled in this study, and in every case, 125Ⅰ-seeds were planted into tumor mass guided by CT. Serum CEA, CA125, NSE and CYFRA21-1 were detected by radioimmunoassay in lung cancer patients before and after planting. The therapeutic effect was evaluated by WHO standards. The relation between the therapeutic effect and the tumor markers levels was observed. Results Just one month after planting, the levels of serum CEA, CA125, NSE and CYFRA21-1 were induced significantly in all cases. There was no significant difference among 1 month, 3 month and 6 month in the levels of tumor markers after therapy. Conclusion 125Ⅰ-seed could effectively decrease the level of tumor markers in the treatment of lung cancer patients.
出处
《中国肺癌杂志》
CAS
2009年第2期135-138,共4页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
125Ⅰ粒子
CT
肿瘤标志物
Lung neoplasms
125Ⅰ-seed
Contraindications
Biological tumor markers
